Related references
Note: Only part of the references are listed.Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
P. Hadji et al.
ANNALS OF ONCOLOGY (2011)
Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence
Gennaro Daniele et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence
A. De Censi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
Georg Pfeiler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
Michael Gnant et al.
LANCET ONCOLOGY (2011)
Breast-Cancer Adjuvant Therapy with Zoledronic Acid
Robert E. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
H. Eidtmann et al.
ANNALS OF ONCOLOGY (2010)
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial
Ivana Sestak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
M. Rabaglio et al.
ANNALS OF ONCOLOGY (2009)
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
Stephanie L. Hines et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Endocrine Effects of Adjuvant Letrozole Compared With Tamoxifen in Hormone-Responsive Postmenopausal Patients With Early Breast Cancer: The HOBOE Trial
Emanuela Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole
Nigel J. Bundred et al.
CANCER (2008)
Endocrine effects of adjuvant letrozole plus triptorelin compared with tamoxifen plus triptorelin in premenopausal patients with early breast cancer
Emanuela Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
Richard Eastell et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer:: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Michael Gnant et al.
LANCET ONCOLOGY (2008)
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
Adam Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
Michael F. X. Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Aromatase inhibitors and bone health in women with breast cancer
Amy Jo Chien et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCICCTG MA.17
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
N Normanno et al.
ENDOCRINE-RELATED CANCER (2005)
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women
HM Heshmati et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Share Paper
